Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with topotecan as second-line treatment for patients with extensive stage small cell lung cancer.
Extensive Stage Small Cell Lung Cancer
DRUG: nab-paclitaxel|DRUG: Topotecan
Overall survival (OS), OS was defined as the time from the date of the first administration of trial regimen to the date of death from any cause (event) or last follow-up (censored data)., 1 years post treatment
Objective response rate (ORR), Response evaluation disease progression defined by Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) criteria.

Response (PR), refers to the number of cases with complete and partial response after treatment as a percentage of the total number of evaluable cases., 1 years|Progression free survival (PFS), The time from treatment to tumor progression or death, 1 years|Adverse events (AE), Adverse events (AE) were monitored on an ongoing basis and classified according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Patients were assessed for toxicities before each administration, and toxicity was graded accordingly, 3 years
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with topotecan as second-line treatment for patients with extensive stage small cell lung cancer.